Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mariangela Ciccarese et al.|The Breast|2018Cited by 35
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective studyGrazia Arpino, Sabino De Placido, Andrea Michelotti et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 15
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maïo, Grazia Arpino, Claudia Bighin et al.|The Breast|2023Cited by 9
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Grazia Arpino, Massimo Di Maïo et al.|Oncotarget|2017Cited by 3